Buprenorphine
- Generic Name
- Buprenorphine
- Brand Names
- Belbuca, Brixadi, Buprenex, Buprenorphine, Butrans, Sublocade, Suboxone, Subutex, Zubsolv, Buvidal, Sixmo
- Drug Type
- Small Molecule
- Chemical Formula
- C29H41NO4
- CAS Number
- 52485-79-7
- Unique Ingredient Identifier
- 40D3SCR4GZ
- Background
Buprenorphine is a weak partial mu-opioid receptor agonist and a weak kappa-opioid receptor antagonist used for the treatment of severe pain. It is also commonly used as an alternative to methadone for the treatment of severe opioid addiction. Buprenorphine is commercially available as the brand name product Suboxone which is formulated in a 4:1 fixed-dose c...
- Indication
Buprenorphine is available in different formulations, such as sublingual tablets, buccal films, transdermal films, and injections, alone or in combination with naloxone.
...
- Associated Conditions
- Opioid Dependence, Severe Pain, Moderate Opioid Dependence, Moderate Pain, Severe Opioid Dependence
- Associated Therapies
- -
Study of the Treatment of Experimental Pain in Opioid Dependent Persons on Methadone or Buprenorphine Maintenance
- Conditions
- Interventions
- First Posted Date
- 2012-07-17
- Last Posted Date
- 2017-09-11
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 132
- Registration Number
- NCT01642030
- Locations
- 🇺🇸
Behavioral Pharmacology Research Unit, Baltimore, Maryland, United States
Efficacy Study to Evaluate Buprenorphine HCl Buccal Film in Opioid-Naive Subjects
- First Posted Date
- 2012-07-06
- Last Posted Date
- 2017-02-27
- Lead Sponsor
- BioDelivery Sciences International
- Target Recruit Count
- 752
- Registration Number
- NCT01633944
- Locations
- 🇺🇸
Peninsula Research, Ormond Beach, Florida, United States
🇺🇸Stamford Therapeutics Consortium, Stamford, Connecticut, United States
🇺🇸Eastern Research, Inc., Hialeah, Florida, United States
Duration of Analgesic Effect for Ultrasound Guided Supraclavicular Blocks With the Addition of Buprenorphine to Local Anesthetic Solution
- Conditions
- Interventions
- First Posted Date
- 2012-04-23
- Last Posted Date
- 2019-09-11
- Lead Sponsor
- University of Wisconsin, Madison
- Target Recruit Count
- 26
- Registration Number
- NCT01583179
- Locations
- 🇺🇸
University of Wisconsin, Madison, Wisconsin, United States
Fetal and Infant Effects of Maternal Buprenorphine Treatment
- First Posted Date
- 2012-03-22
- Last Posted Date
- 2017-09-26
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 127
- Registration Number
- NCT01561079
- Locations
- 🇺🇸
Center for Addiction and Pregnancy, Baltimore, Maryland, United States
🇺🇸Johns Hopkins Bayview Medical Center, Baltimore, Maryland, United States
Reducing Drug Use and HIV Risk in Drug-dependent Adults Arrested for Prostitution
- Conditions
- Interventions
- First Posted Date
- 2012-03-22
- Last Posted Date
- 2014-12-11
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 38
- Registration Number
- NCT01560221
- Locations
- 🇺🇸
The Center for Learning and Health, Baltimore, Maryland, United States
Buprenorphine in Acute Renal Colic Pain Management
- Conditions
- Interventions
- First Posted Date
- 2012-03-07
- Last Posted Date
- 2012-12-10
- Lead Sponsor
- Tehran University of Medical Sciences
- Target Recruit Count
- 80
- Registration Number
- NCT01546701
- Locations
- 🇮🇷
TUMS, Tehran, Iran, Islamic Republic of
Buprenorphine for Treatment Resistant Depression
- Conditions
- Interventions
- First Posted Date
- 2011-08-02
- Last Posted Date
- 2018-03-09
- Lead Sponsor
- University of Pittsburgh
- Target Recruit Count
- 13
- Registration Number
- NCT01407575
- Locations
- 🇺🇸
Western Psychiatric Institute and Clinic, University of Pittsburgh, Pittsburgh, Pennsylvania, United States
Improved Strategies for Outpatient Opioid Detoxification
- Conditions
- Interventions
- First Posted Date
- 2011-06-21
- Last Posted Date
- 2018-05-21
- Lead Sponsor
- New York State Psychiatric Institute
- Target Recruit Count
- 150
- Registration Number
- NCT01377610
- Locations
- 🇺🇸
Substance Treatment and Research Service (STARS), Columbia University, New York, New York, United States
Study Assessing the Safety and Therapeutic Effect of Buprenorphine in MDD Patients
- First Posted Date
- 2011-03-09
- Last Posted Date
- 2012-09-25
- Lead Sponsor
- Shalvata Mental Health Center
- Target Recruit Count
- 20
- Registration Number
- NCT01311570
- Locations
- 🇮🇱
Shalvata Medical Health Center, Hod-Hasharon, Israel
Efficacy of Buprenorphine for Treatment of Acute Pain
- First Posted Date
- 2011-02-17
- Last Posted Date
- 2012-12-10
- Lead Sponsor
- Tehran University of Medical Sciences
- Target Recruit Count
- 80
- Registration Number
- NCT01298297
- Locations
- 🇮🇷
Emergency Department, Imam Hospital, Tehran, Iran, Islamic Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.